FDA Guides Drug Makers to Faster Generic Copies
Published Date: 2/27/2026
Notice
Summary
The FDA just released new draft guides to help drug makers design tests proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by April 28, 2026, before these guides become official. These updates aim to speed up drug approvals, saving time and money for everyone.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA Posts Draft BE Study Guidances
The FDA posted new draft and revised draft product-specific guidances that give recommendations for designing bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). The notice lists many active ingredients covered (for example: apixaban, buprenorphine, semaglutide, tadalafil, acetaminophen, and others) and the FDA is accepting comments on these drafts through April 28, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16728, Gastroenterology-Urology Devices; Reclassification of Diagnostic Endoscopic Light Source Systems To Be Renamed Cystoscopic Systems Intended as an Aid for Detection of Bladder Cancer
The Food and Drug Administration (FDA) is proposing to reclassify diagnostic endoscopic light source systems (product code OAY), which are postamendments class III devices, from class III (premarket approval) into class II (special controls), subject to premarket notification. FDA is also proposing a new device classification regulation with the name "Cystoscopic system intended as an aid for detection of bladder cancer," along with special controls that FDA believes are necessary to provide a reasonable assurance of the safety and effectiveness of these devices.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16727, Hematology and Pathology Devices; Reclassification of In Situ Hybridization Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product
The Food and Drug Administration (FDA, the Agency, or we) is issuing a final order reclassifying in situ hybridization (ISH) test systems indicated for use with a corresponding approved oncology therapeutic product (product codes NYQ, MVD, OWE, and PNK), all postamendments class III (premarket approval) devices, into class II (special controls), subject to premarket notification. FDA is also establishing a new device classification regulation, along with the special controls that are necessary to provide a reasonable assurance of safety and effectiveness of this device type.
Previous / Next Documents
Previous: 2026-03961, Fiscal Year 2026 Generic Drug Science and Research Initiatives Workshop; Public Workshop; Request for Comments
The FDA is hosting a fun and important workshop on June 8-9, 2026, to talk about new science and research for generic drugs. They want input from drug makers, scientists, patients, and anyone interested to help shape next year’s plans. If you want to share your thoughts, make sure to send comments by July 10, 2026—this helps improve affordable medicine for everyone!
Next: 2026-03964, Intertek Testing Services NA, Inc.: Application for Expansion of Recognition
Intertek Testing Services NA, Inc. wants to expand its role as a trusted safety tester recognized by OSHA. This means they can test more products to make sure they’re safe for workers and the public. If you have thoughts or info, you’ve got until March 16, 2026, to speak up—this could speed up safety checks and impact businesses relying on testing.